How Globus Medical, Inc. stacks up

GMED · against 552 other Healthcare companies listed in US-listed

Overall

78/ 100

Near the top of its peers.

Ranked #17 of 553 · scores higher than 97% of peers

Bars: peers in each 10-point band of the overall score

33 peers with an overall score of 70–79, including GMED · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#59 of 589Score 77 / 100 · beats 90%Growth#110 of 455Score 85 / 100 · beats 75%Profitability#82 of 558Score 84 / 100 · beats 85%Risk#216 of 597Lower relative risk · safety 67 · beats 64%

Ranking by overall score

Top 5 and the companies ranked around GMED

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	Arbutus Biopharma CorporationABUS · US-listed	595M USD	97	96	98	99	0 / 2
1	Q32 Bio Inc.QTTB · US-listed	261M USD	97	93	—	98	0 / 2
3	Lakefront Biotherapeutics NVLKFT · US-listed	2.1B USD	96	96	99	93	0 / 2
4	Innoviva, Inc.INVA · US-listed	1.5B USD	93	94	91	93	0 / 2
5	Zevra Therapeutics, Inc.ZVRA · US-listed	609M USD	91	95	99	99	0 / 2
⋯
11	Inspire Medical Systems, Inc.INSP · US-listed	1.8B USD	80	75	83	76	0 / 2
14	ADMA Biologics, Inc.ADMA · US-listed	2.5B USD	79	81	67	98	0 / 2
14	argenx SEARGX · US-listed	56.7B USD	79	42	96	93	0 / 2
14	LeMaitre Vascular, Inc.LMAT · US-listed	1.8B USD	79	59	74	90	0 / 2
17	Globus Medical, Inc.GMED · US-listed	10.7B USD	78	77	85	84	0 / 2
17	Harmony Biosciences Holdings, Inc.HRMY · US-listed	2.2B USD	78	92	75	95	1 / 2
17	Krystal Biotech, Inc.KRYS · US-listed	9.0B USD	78	50	80	94	0 / 2
17	Ligand Pharmaceuticals IncorporatedLGND · US-listed	6.3B USD	78	50	90	86	0 / 2
21	ANI Pharmaceuticals, Inc.ANIP · US-listed	1.7B USD	77	89	89	85	1 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

Bringing the fundamentals into focus…